Ibrutinib
- PDF / 169,751 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 15 Downloads / 167 Views
1
S
Bleeding: 9 case reports In a retrospective cohort study of 565 patients, 9 patients [ages and sexes not stated] were described, who developed GI bleeding, CNS bleeding, rectal bleeding or bleeding secondary to multiple-splenic/liver laceration during treatment with ibrutinib for multiple B-cell malignancy [dosages, routes and time to reactions onset not stated; not all outcomes stated]. The patients received ibrutinib. Three patients had also been receiving an unspecified anticoagulation therapy. Subsequently, the patients developed GI bleeding (n=4), CNS bleeding (n=2), rectal bleeding (n=2) or bleeding secondary to multiple-splenic/liver laceration (n=1). Ibrutinib was held in two of these 9 patients. Four of these 9 patients were subjected to blood transfusion. Three of these 9 patients died due to bleeding; haemorrhagic conversion of a cerebrovascular accident (two patients) or motor vehicle accident (one patient). Author comment: "Following a thrombotic event, patients were evaluated for recurrent thrombosis and bleeding. There were nine bleeding events: four major and five minor. Three patients died due to bleeding: two after haemorrhagic conversion of a [cerebrovascular accident] and one after a motor vehicle accident." "[I]brutinib’s inhibition of BTK and Tec in platelets as an anti-platelet effect, which are proposed mechanisms for its bleeding toxicity." Kander EM, et al. Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. British Journal of Haematology 187: 399-402, No. 3, Nov 2019. Available from: URL: http://doi.org/10.1111/bjh.16209 803438263 - USA
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
